Press Release Distribution
 

Members Login  |  Register  |  Why Join?   Subscribe to Newsletter Newsletter   RSS Feeds RSS Feeds

Video Releases    |    Pricing & Distribution Plans    |    Today's News    |    News By Category    |    News By Region    |    News By Date    |    Business Directory
All Press Releases for July 31, 2010 »
RSS Feeds RSS Feed     Print this news Printer Friendly     Email this news Email It    Create PDF PDF Version    Bookmark del.icio.us    Diggs



Clinical Pharmacology Study Group (CPSG) Announces Open Enrollment for Diabetic Neuropathy
Trials open for several diseases at our Worcester, MA site, including diabetic neuropathy. 
x-small text small text medium text large text


    WORCESTER, MA, July 31, 2010 /24-7PressRelease/ -- The Clinical Pharmacology Study Group (CPSG) is currently participating in several clinical trials for diabetic peripheral neuropathy in its Worcester, MA facility.

Diabetic neuropathy is a common complication of diabetes in which nerves are damaged as a result of high blood sugar levels. Symptoms of diabetic neuropathy include pain, tingling, or numbness and loss of feeling in the hands, arms, feet, and legs. Nerve problems can occur in every organ system, including the digestive tract, heart, and sex organs. About 60 to 70 percent of people with diabetes have some form of neuropathy. This clinical study is specifically for diabetic peripheral neuropathy.

Subjects who enroll in a clinical trial are carefully selected from a list of inclusion and exclusion criteria designed to ensure safety for the subject. Patients' selected to participate in this study are followed by a team of experts in diabetic peripheral neuropathy. All study related medications and care are at no cost to the patient. The study group works closely with the patient care provider (PCP), or other specialist, to ensure that all the medical professionals are involved in the treatment of the patient.

"Total patient care is our top priority at CPSG. We educate and treat the individual about the disease and the study. If our medical team concludes that the patient would be better served with an alternative medical treatment, we will help coordinate that care for patients. We pride ourselves in offering superior patient care throughout the study," stated Mary Coughlin, RN and Partner of CPSG.

If you want to learn more or enroll in this local study, please contact the:

Clinical Pharmacology Study Group
UMASS Memorial City Campus
26 Queen Street, Worcester, MA 01610
Phone: 508-755-0201
info@cpsgma.com
http://www.cpsgma.com

About Clinical Pharmacology Study Group
The Clinical Pharmacology Study Group (CPSG) was established in 1989 in Worcester, Massachusetts by Doctor Birbara and Mary Coughlin, RN. The group has been involved in the field of rheumatology study since 1975. The practice has worked with traditional anti-inflammatory medications (NSAIDs) in conjunction with stomach protecting agents. The group has a history of working with Celebrex, Vioxx, Bextra, and other COX II inhibitors. In the late 1990's, we entered the era of biologics for the treatment of rheumatoid arthritis (RA).

CPSG is continuing to expand work with biologicals in the areas of rheumatoid arthritis, psoriasis, psoriatic arthritis and Chrohn's disease. CPSG is also participating in many new trials for fibromyalgia, osteoarthritis, osteoporosis, gout, and lower back pain.

CONTACT:
Deborah A. Buckley
Phone: +1.978.466-7637
Email: dbuckley@emarketing4us.com


---
Press release service and press release distribution provided by http://www.24-7pressrelease.com


# # #

Read more Press Releases from Mary Coughlin:


Press Release Service & Press Release Distribution News Supplied By 24-7PressRelease.com
Press Release Contact Information:
Mary Coughlin
CPSG

Coordinator
26 Queen St.
Worcester, MA
USA 01610
Voice: 508-755-0201
Fax: 508-755-8909
E-Mail: Email us Here
Website: Visit Our Website
Disclaimer:
If you have any questions regarding information in this press release, please contact the person listed in the contact module of this page. Please do not attempt to contact 24-7 Press Release. We are unable to assist you with any information regarding this release. 24-7 Press Release disclaims any content contained in this press release. Please see our complete Terms of Service disclaimer for more information.